Cystic fibrosis once all but guaranteed an early death. When the disease was first identified, in the 1930s, most babies born with CF died in infancy. The next decades were a grind of incremental medical progress: A child born with CF in the ’50s could expect to live until age 5. In the ’70s, age 10. In the early 2000s, age 35. With Trikafta came a quantum leap. Today, those who begin taking the drug in early adolescence, a recent study projected, can expect to survive to age 82.5—an essentially normal life span.
Of course, there are issues:
- Side effects: “It can cause cataracts as well as liver injury. More perplexing, Trikafta may affect the brain. For Jenny, starting Trikafta coincided with a wave of intense insomnia, brain fog, and anxiety.”
- Trikafta repairs the results of a specific mutation: “For another group of CF patients, Trikafta simply does not work. About 10 percent lack the F508del mutation that the triple combination was specifically designed to fix.”
- Since so many people have been more or less cured, support groups for CF patient have been disappearing, even for the 10% who are not helped by Trikafta: “Recently, Make-A-Wish announced that children with CF would no longer automatically be eligible for the program, because “life-changing advances” had radically improved the outlook for them.”
- And… CF patients expected to die young. Often they have no savings, no professional skills, no kids, because they did not expect to live long enough to deal with those. But now they will live.
7,700 words but all interesting: https://www.theatlantic.com/magazine/archive/2024/04/cystic-fibrosis-trikafta-breakthrough-treatment/677471/. Send me a note if you can’t read it.
